Last updated: July 31, 2026
DURAGESIC-50 is the 50 mcg/hour strength of the fentanyl transdermal system, a long-acting opioid patch indicated for opioid-tolerant patients with severe, persistent pain. Its branded U.S. exclusivity has expired, generic fentanyl patches are widely approved, and no active branded development program materially changes its competitive position. Market value is concentrated in generic transdermal fentanyl, hospital and specialty-pain channels, and non-U.S. markets rather than in the Duragesic brand.
What is DURAGESIC-50 and how does the fentanyl patch work?
DURAGESIC-50 delivers fentanyl through the skin at a nominal rate of 50 micrograms per hour for up to 72 hours. The system is intended for patients already receiving chronic opioid therapy and is not indicated for opioid-naive patients, acute pain, postoperative pain, or intermittent pain.
The product has a delayed pharmacokinetic profile. Serum fentanyl concentrations generally rise gradually after application, reach a plateau, and decline slowly after removal because fentanyl remains in the skin depot. The FDA label warns that respiratory depression can persist after the patch is removed. Heat exposure can increase fentanyl absorption and has been associated with fatal overdose risk.[1]
| Attribute |
DURAGESIC-50 |
| Active ingredient |
Fentanyl |
| Dosage form |
Transdermal patch |
| Nominal delivery rate |
50 mcg/hour |
| Typical wear duration |
Up to 72 hours |
| Therapeutic category |
Long-acting opioid analgesic |
| U.S. indication |
Opioid-tolerant patients with severe, persistent pain |
| Originator |
Janssen Pharmaceuticals, historically under Johnson & Johnson |
| U.S. regulatory status |
Approved prescription drug; generic competition established |
| Biosimilar relevance |
None; this is a chemically synthesized small molecule |
| Main substitutes |
Generic fentanyl patches, extended-release oral opioids, buprenorphine patches, implanted and non-opioid pain therapies |
What is the current clinical-trial status of DURAGESIC-50?
No active clinical-trial program is expected to generate new branded indications or extend the commercial life of DURAGESIC-50. The product is an established delivery system with decades of postmarketing experience, and current research is directed mainly toward opioid safety, abuse deterrence, chronic-pain outcomes, overdose prevention, and alternative analgesics.
Historical clinical development established the efficacy of transdermal fentanyl for chronic pain in opioid-tolerant patients. Later studies and regulatory actions focused on safety rather than new efficacy claims. Key risk areas include respiratory depression, accidental exposure, misuse, medication errors, heat-related overdose, and inappropriate use in opioid-naive patients.[1,2]
What clinical evidence supports the 50 mcg/hour strength?
The 50 mcg/hour system is one step in a dose range that commonly includes 12, 25, 50, 75, and 100 mcg/hour systems. Dose selection is based on the patient’s prior opioid exposure, clinical response, tolerability, and the need for titration.
The FDA conversion tables are not intended to support automatic one-to-one substitution among opioids. Conversion errors can produce fatal respiratory depression. The label requires conservative conversion and monitoring during initiation and dose changes.[1]
What safety studies affect the DURAGESIC-50 outlook?
The strongest current evidence base concerns opioid risk management rather than product expansion:
- FDA labeling restricts use to opioid-tolerant patients.
- Heat sources, fever, hot tubs, heating pads, and intense exercise can increase drug delivery.
- Accidental transfer to children or other individuals can cause fatal exposure.
- CYP3A4 inhibitors can increase fentanyl exposure.
- Concomitant benzodiazepines, alcohol, or other central nervous system depressants increase respiratory-depression risk.
- Used patches retain fentanyl and require controlled disposal.[1]
FDA’s opioid policy actions and postmarketing surveillance reduce the probability of a new broad indication for the product. They also increase compliance costs for manufacturers and distributors.[2]
When did DURAGESIC-50 lose exclusivity?
DURAGESIC-50 no longer has meaningful U.S. market exclusivity. The original product patents and regulatory exclusivities expired years ago, enabling multiple abbreviated new drug applications for fentanyl transdermal systems.
The Orange Book lists approved fentanyl transdermal systems and related patent information where applicable. A product-specific patent portfolio is no longer the principal barrier to U.S. generic entry. Commercial barriers now include manufacturing validation, controlled-substance compliance, patch adhesion and drug-release performance, bioequivalence, supply reliability, and state-level opioid restrictions.[3]
| Exclusivity issue |
Current position |
| New chemical entity exclusivity |
Expired |
| Original brand patent protection |
Expired |
| Pediatric exclusivity |
No current commercial significance |
| Formulation exclusivity |
Expired or bypassed by approved generic systems |
| Orange Book competition |
Multiple generic fentanyl transdermal systems |
| Biosimilar pathway |
Not applicable |
| Current protection |
Regulatory compliance, manufacturing know-how, trademarks, contracts, and supply-chain execution |
What patents protect DURAGESIC-50?
The historical Duragesic estate covered fentanyl delivery through the skin, patch construction, drug reservoirs, adhesives, and related transdermal-system technology. The relevant commercial position has shifted from patent protection to approved product equivalence and manufacturing capability.
Brand-specific claims involving the Duragesic trademark remain separate from patent rights. Generic manufacturers cannot market under the Duragesic name, but they can sell therapeutically equivalent fentanyl transdermal systems if approved by FDA.
Patent challenges involving early generic fentanyl patches centered on whether the generic systems infringed or validly avoided transdermal delivery patents. Those disputes no longer prevent broad generic availability. Current entrants would more likely encounter quality, bioequivalence, inspection, or supply issues than a durable blocking patent.
What is the Orange Book status of DURAGESIC-50?
The Orange Book framework treats the product as a prescription drug with approved generic equivalents rather than as a protected branded product. Generic fentanyl patches generally rely on the abbreviated new drug application pathway and must demonstrate pharmaceutical equivalence and bioequivalence to the relevant reference product.[3]
Orange Book-listed patents can remain relevant to individual strengths, manufacturing methods, or later-approved formulations. They do not restore the historical exclusivity of the original Duragesic product. A complete litigation review must distinguish:
- patents listed for the reference product;
- patents asserted in ANDA litigation;
- patents covering a particular generic’s formulation or manufacturing process; and
- patents that have expired, been disclaimed, or become commercially irrelevant.
Which companies compete with DURAGESIC-50?
The primary U.S. competitors are generic manufacturers of fentanyl transdermal systems. Market participants have included firms such as Actavis, Mylan, Teva, and other approved ANDA holders, although product availability and marketing status can change by manufacturer and strength.
The competitive field also includes non-fentanyl alternatives:
- buprenorphine transdermal systems for selected chronic-pain patients;
- extended-release oxycodone and morphine;
- methadone and other long-acting opioid regimens;
- non-opioid pharmacologic therapies;
- interventional pain procedures;
- implantable drug-delivery systems.
Fentanyl patches retain clinical utility where patients require stable delivery and cannot reliably use oral medication. They face structural pressure from opioid stewardship, prescribing restrictions, abuse concerns, and the availability of alternative formulations.
How strong is the patent estate for DURAGESIC-50?
The current patent estate is commercially weak for blocking purposes. The original platform patents have aged out, and generic entry is established. Residual intellectual-property value may exist in:
- adhesive composition;
- low-residue or skin-friendly patch designs;
- abuse-deterrent systems;
- packaging and disposal technology;
- manufacturing controls;
- improved adhesion in heat or high-moisture conditions;
- digital adherence or monitoring systems.
These features could support new products, but they would not recreate exclusivity for the legacy DURAGESIC-50 patch without a separately approved product and defensible patent claims.
What manufacturing barriers remain?
Manufacturing is more important than patent protection. Fentanyl is a highly potent controlled substance, and manufacturers must manage:
- controlled-substance quotas and records;
- containment and worker exposure;
- uniform drug loading;
- adhesive performance;
- transdermal flux;
- residual fentanyl in used patches;
- stability and packaging;
- batch-to-batch delivery-rate consistency;
- diversion controls.
FDA has identified manufacturing quality and supply continuity as important factors in generic drug availability. A technically approved product can still lose share if it cannot maintain reliable supply.
What litigation and Paragraph IV risks affect DURAGESIC-50?
The major Paragraph IV wave occurred during the original generic-entry period. Those challenges targeted patents associated with fentanyl transdermal delivery and patch design. Since several generic systems are already marketed, a new Paragraph IV challenge would have limited strategic value unless it addressed a later formulation, a specific listed patent, or an underserved strength.
Current litigation risk is more likely to arise from:
- alleged patent infringement involving a new patch architecture;
- product liability claims involving overdose or accidental exposure;
- manufacturing and quality disputes;
- controlled-substance distribution enforcement;
- trademark or false-advertising claims;
- contract disputes over supply and authorized distribution.
No current settlement agreement is known to create a broad market-wide barrier to generic fentanyl patch entry. Generic competition is already embedded in the U.S. market.
What is the FDA regulatory status of DURAGESIC-50?
DURAGESIC-50 remains an FDA-approved prescription product under opioid labeling that emphasizes restricted patient selection and overdose prevention. The FDA’s regulatory posture is not expansionary. It favors risk controls, opioid-tolerant use, medication-error reduction, and postmarketing surveillance.[1,2]
The main regulatory risks are:
- label revisions after new safety findings;
- manufacturing observations or recalls;
- shortages affecting specific strengths;
- distribution restrictions;
- changes in opioid prescribing guidance;
- enforcement involving diversion or improper promotion.
The product is not a biologic and has no biosimilar exposure. Its generic pathway is the ANDA system, not the abbreviated biologics licensing pathway.
What is the DURAGESIC-50 market size and revenue exposure?
Standalone global revenue for the DURAGESIC-50 brand is not a reliable public market metric because sales are commonly aggregated with other Duragesic strengths, generic fentanyl patches, or broader transdermal analgesic categories. The brand’s revenue exposure is materially lower than during its exclusivity period because generic substitution has compressed price and share.
The commercial model is characterized by:
| Driver |
Effect on DURAGESIC-50 |
| Generic substitution |
Strong downward pressure on brand volume and price |
| Chronic-pain prescribing controls |
Reduces eligible patient population |
| Opioid-tolerant indication |
Limits new-patient starts |
| Hospital and specialty use |
Supports persistent niche demand |
| Supply disruptions |
Can shift volume among generic suppliers |
| Buprenorphine competition |
Reduces use in some chronic-pain segments |
| Opioid litigation and policy |
Raises compliance and liability costs |
| Brand recognition |
Provides limited value where substitution is automatic |
Revenue is more defensible for the overall fentanyl transdermal segment than for the DURAGESIC-50 brand alone. The segment should remain a mature, low-growth or declining category in the U.S., with unit demand constrained by opioid stewardship and pricing reduced by generic competition.
What is the projected market outlook for DURAGESIC-50?
The base-case outlook is stable-to-declining U.S. unit demand and continued price erosion. The brand is unlikely to regain meaningful share without a differentiated delivery system, new indication, or supply disruption affecting generics.
Base case, 2025-2030
- U.S. branded Duragesic revenue: continued erosion and limited commercial relevance.
- Generic fentanyl patch volume: broadly stable in chronic-pain niches, with periodic supply volatility.
- Average selling prices: downward pressure from multiple ANDA holders.
- Clinical use: concentrated in opioid-tolerant patients with persistent pain and limited oral options.
- Innovation: likely to focus on safer delivery, adhesion, disposal, and abuse-deterrence rather than the legacy patch.
- Competitive risk: moderate from buprenorphine and non-opioid therapies; high from generic substitution.
Upside scenario
An upside case would require a supply shortage among generic competitors, re-entry by a branded manufacturer with dependable distribution, or a differentiated patch that improves adhesion, reduces accidental exposure, or supports safer prescribing. These conditions could increase price or share temporarily but would not restore the original patent-based economics.
Downside scenario
The downside case includes tighter opioid restrictions, additional fentanyl safety warnings, product recalls, reduced payer coverage, or a shift toward buprenorphine and non-opioid pain management. These factors could reduce both unit volume and treatment duration.
How does DURAGESIC-50 compare with buprenorphine patches?
| Factor |
Fentanyl transdermal 50 mcg/hour |
Buprenorphine transdermal patch |
| Opioid potency |
Higher |
Lower |
| Typical role |
Opioid-tolerant patients with severe persistent pain |
Selected chronic-pain patients requiring lower-dose therapy |
| Generic competition |
Extensive |
Also present, depending on market |
| Respiratory-depression risk |
High |
Lower relative risk, but still present |
| Dose conversion |
Complex and potentially hazardous |
Also requires clinical judgment |
| Commercial trend |
Mature and pressured |
Competitive alternative in selected patients |
| Biosimilar relevance |
None |
None |
The products are not interchangeable. Patient selection, prior opioid exposure, dose requirements, and labeling restrictions control the clinical comparison.
Key Takeaways
- DURAGESIC-50 is a 50 mcg/hour fentanyl transdermal patch for opioid-tolerant patients with severe, persistent pain.
- No active branded clinical-trial program is expected to create a new indication or extend exclusivity.
- U.S. patent and regulatory exclusivity have expired, and generic fentanyl patches are established.
- The Orange Book position supports an ANDA-driven competitive market.
- Biosimilar risk is irrelevant because fentanyl is a small-molecule drug.
- Current commercial barriers are manufacturing quality, controlled-substance compliance, supply reliability, and bioequivalence.
- U.S. branded revenue is expected to remain limited, while the generic segment faces stable-to-declining demand and price pressure.
- The principal clinical risks are respiratory depression, heat-related overdose, accidental exposure, misuse, and opioid co-medication.
- Future value would depend on differentiated patch technology rather than the legacy DURAGESIC-50 formulation.
FAQs
Is DURAGESIC-50 still available in the United States?
Fentanyl transdermal systems in the 50 mcg/hour strength are available through generic manufacturers, while branded Duragesic availability depends on commercial distribution and market-specific supply.
Can a patient switch directly from DURAGESIC-50 to a generic fentanyl patch?
A pharmacist may substitute an FDA-authorized therapeutically equivalent product where permitted, but any change in patch product should be managed under the prescribing and dispensing requirements applicable to the specific product.
Does DURAGESIC-50 have pediatric exclusivity?
No current pediatric exclusivity materially protects the product’s commercial position. Its market is governed primarily by the approved opioid-tolerant indication and safety restrictions.
Are fentanyl patch manufacturers exposed to biosimilar competition?
No. Fentanyl is a chemically synthesized small molecule. Competition occurs through generic drug applications rather than biosimilar applications.
What would make a new fentanyl patch commercially differentiated?
The strongest differentiation opportunities are improved adhesion, reduced accidental transfer, abuse deterrence, safer disposal, more predictable delivery under heat exposure, and manufacturing systems that reduce variability and contamination risk.
References
- U.S. Food and Drug Administration. (2023). Duragesic (fentanyl transdermal system) prescribing information.
- U.S. Food and Drug Administration. (2020). FDA development and approval process for opioid analgesics and opioid safety communications.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Drug Enforcement Administration. (2024). Controlled substances regulations and quota management.
- National Library of Medicine. (2024). ClinicalTrials.gov: Fentanyl transdermal system and chronic pain studies.
